期刊文献+

PTEN信号转导通路与肿瘤的多药耐药 被引量:15

PTEN signaling pathways and multidrug resistance of tumor
下载PDF
导出
摘要 基因调控、信号转导通路异常均可引起细胞增殖失控,导致肿瘤发生。肿瘤细胞对化疗药物耐药是肿瘤患者死亡的主要原因。细胞内药物有效浓度的降低、DNA损伤的修复障碍、基因的突变及异常表达、信号转导通路的异常等均参与了肿瘤细胞的多药耐药。张力蛋白同源10号染色体缺失的磷酸酶基因(phosphatase and tension homology deleted on chromosometen gene,PTEN)是具有磷酸酶活性的抑癌基因,在多种肿瘤细胞中异常表达,主要通过抑制PI3K/Akt/mTOR(mammalian targetof rapamycin,mTOR)等多种信号转导通路参与细胞的增殖、凋亡及化疗耐药。因此,上调野生型PTEN的表达,或使用PI3K/Akt/mTOR信号通路抑制剂,可逆转肿瘤细胞的多药耐药,提高传统化疗的疗效。
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2009年第4期413-417,共5页 Chinese Journal of Cancer Biotherapy
基金 河北省科技攻关计划项目(No.072761130)~~
  • 相关文献

参考文献27

  • 1Myers MP, Stolarov JP, Eng C, et al. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase [J]. Proc Natl Acad Sci U S A, 1997,94(17) : 9052-9057.
  • 2Li J, Yen C, Liow D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J]. Science, 1997, 275(5308): 1943-1947.
  • 3Dahia PL, Aguiar RC, Alberta J, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via muhiple mechanisms in hematological malignancies [ J]. Hum Mol Genet, 1999, 8(2) : 185-193.
  • 4Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts [J]. Genes Dev, 1999, 13(22) : 2905-2927.
  • 5Shen YN, Zhang L, Gan Y, et al. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling [J]. J Biol Chem, 2006, 281 (12) : 7727-7736.
  • 6Wee KB, Aguda BD. Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death [ J]. Biophys J, 2006, 91 (4): 857-865.
  • 7Vasudevan KM, Gurvmunhy S, Rangnekar VM. Suppression of PTEN expression by NF-kappaB prevents apoptosis [ J]. Mol Cell Biol, 2004, 24(3): 1007-1021.
  • 8Peponi E, Drakos E, Reyes G, et al. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma [ J ]. Am J Pathol, 2006, 169(6) : 2171-2180.
  • 9Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies [ J ]. Cancer, 2004, 100 (4) : 657-666.
  • 10Sehondof T, Becker M, Gohring U J, et al. Interaction of eisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN [ J ]. Anticancer Drugs, 2001, 12(10) : 797-780.

二级参考文献30

  • 1Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors [J].Breast Cancer Res Treat, 2005, 91(2) : 187-201.
  • 2Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptininduced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action[J].Cancer Res, 2002, 62(14) : 4132-4141.
  • 3Pandolfi PP. Breast cancer-loss of PTEN predicts resistance to treatment[J]. N Engl J Med, 2004, 351 (22) : 2337-2338.
  • 4Fujita T, Doihara H, Washio K, et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumabinduced growth inhibition in trastuzumab-resistant cells[ J ]. Anticancer Drugs, 2006, 17(4) : 455-462.
  • 5Lohrish C, PiccartM. An overview of HER2 [ J]. Semin Oncol, 2001,28(6 Suppl 18) : 3-11.
  • 6Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications [ J]. Ann N Y Acad Sci, 2005, 1059 : 70-75.
  • 7Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer[J]. Nat Clin Pract Oncol, 2006, 3(5) : 269-280.
  • 8Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line [ J ]. Cancer Res, 2005, 65(2) : 473-482.
  • 9Wang SE, Narasanna A, Perez-Torres M,et al. HER2 kinase do- main mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors[J]. Cancer Cell, 2006, 10(1) : 25-38.
  • 10Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3- kinase signaling network: implications for human breast cancer [J]. Oncogene, 2007, 26(9) : 1338-1345.

共引文献8

同被引文献207

引证文献15

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部